-
0.25 AMA PRA Category 1 Credits™ available
Expiry: June 16, 2026
- Activity time: 25 min
ADVANCES
gMG disease dialogues:
clinical advances and expert insights
Episode 2, part 1 | New and emerging therapies in gMG: FcRn receptor antagonists and complement inhibition
In this two-part episode, Dr. Kelly Gwathmey, MD, and Dr. Pushpa Narayanaswami, MD, FAAN, discuss the evolving landscape of generalized myasthenia gravis (gMG) treatment, including the foundational role of conventional immunotherapies and the emergence of novel agents like FcRn receptor antagonists and complement inhibitors. Learn about the mechanisms, clinical trial data, and practical considerations for integrating these therapies into patient care.
Learn more in part 2: available now!
Meet the experts
Dr. Kelly Gwathmey, MD
Virginia Commonwealth University
Virginia Commonwealth University
Richmond, VA,
United States
Kelly Gwathmey is originally from Richmond, Virginia. She studied neuroscience and behavioral biology at Emory University in Atlanta, Georgia. She then attended Eastern Virginia Medical School in Norfolk, Virginia. Her neurology and clinical neurophysiology training was completed at the University of Virginia. Following this, she completed a neuromuscular medicine fellowship at both Brigham and Women’s Hospital and Massachusetts General Hospital in Boston, Massachusetts. At the University of Virginia, she started the multidisciplinary MDA clinic, was co-director of the ALS clinic, and was the fellowship director for both the neuromuscular and clinical neurophysiology fellowships. She joined Virginia Commonwealth University in January 2019 and currently serves in the capacity of associate professor of neurology, neuromuscular division chair, neuromuscular medicine program director, and EMG laboratory director. Dr. Gwathmey sees a wide spectrum of neuromuscular patients and performs electrodiagnostic studies (nerve conduction studies and electromyography). Her research interests include quality-of-life instruments and autoimmune neuromuscular disorders.
Disclosures
Speakers Bureau/honoraria for non-CME: Alexion pharmaceuticals, argenx
Consultant/advisory board: Alexion pharmaceuticals, Amgen, argenx, UCB
Dr. Pushpa Narayanaswami, MD, FAAN
Beth Israel Deaconess Medical Center / Harvard Medical School
Boston, MA, United States
Dr. Pushpa Narayanaswami, MD, FAAN
Beth Israel Deaconess Medical Center / Harvard Medical School
Beth Israel Deaconess Medical Center / Harvard Medical School
Boston, MA,
United States
Pushpa Narayanaswami is Professor of Clinical Neurology at Harvard Medical School and Vice-Chair of Clinical Operations, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA. She is a fellow of the American Academy of Neurology (AAN). She has authored/co-authored several peer-reviewed articles, invited reviews, editorials, clinical practice guidelines, quality measures, book chapters and edited a book, “Principles and Practice of the Muscular Dystrophies”. She has received federal research funding from the Agency for Healthcare Research and Quality (AHRQ), Patient Centered Outcomes Research Institute (PCORI) and National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). She serves as an associate editor for Muscle & Nerve and as the associate editor, classification of evidence, for Neurology® Journals. She co-chairs the Quality Improvement and Patient Safety Committee of the American Association of Neuromuscular and Electrodiagnostic Medicine.
In her clinical practice she manages neuromuscular conditions, with special emphasis on myasthenia gravis, myopathies and muscular dystrophies. Her research includes clinical trials of new treatments for myasthenia gravis and observational studies of the effectiveness of treatments in clinical practice. She is a methodologist for several guidelines in development. Her work seeks to incorporate research with advocacy and healthcare policy to improve patient care.
Disclosures
Grant/research support: Alexion, Cabaletta Bio, Dianthus, NIAMS, PCORI
Consultant/advisory board: Alexion. argenx, Amgen, CVS Healthcare, Dianthus, ImmunAbs, Janssen, Merck-Serono, Roche, UCB
Non-mutual funds stock ownership/stock options: Dr. Reddy’s Laboratories, Moderna, Pfizer
Patent holder/royalties: Springer-Nature book royalty
Other financial or material support:
-
Data and safety monitoring board member: argenx, Sanofi, NMD Pharma
- Associate editor: Muscle & Nerve and Neurology® Journals
Pressed for time?
Tune in to the audio version of this expert podcast on Spotify, Apple Podcasts, or your favorite podcast platform. Anytime, Anywhere!
Available now:
Voices of gMG video
module
Visit the AWARENESS phase, a compelling patient-physician conversation between Janel and Dr. Gwathmey which yields insights into the lived experiences of patients with gMG and the challenges they face navigating their healthcare journey.
Don’t miss out!
Your ready-to-use toolkit!
Make sure to visit the ACTION phase, a downloadable and printable toolkit of strategies and resources. Expert-authored clinical practice aids and patient guides, to optimize your patient care.
Accreditation
In support of improving patient care, these activities have been planned and implemented by the Postgraduate Institute for Medicine and Springer Healthcare IME. The Postgraduate Insititute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.